Pfizer Plans to Exit Weesp Animal Health Plant in the Netherlands As Part of Global Plant Network Strategy
NEW YORK, June 21, 2010--As part of a strategy to fully align its global Animal Health manufacturing and supply organization, Pfizer Inc today announced its proposal to exit its Weesp plant in The Netherlands. The
recommended exit—along with earlier divestitures of some products and four plants in the United States, Ireland and Australia to gain government approval for the 2009 acquisition of Wyeth/Fort Dodge Animal Health—will reduce the size of the company’s Animal Health plant network by nearly 20 percent.
The proposed exit of the Weesp facility is part of Pfizer’s global effort to improve overall manufacturing efficiency, reduce manufacturing complexity, lower costs and enhance customer service. The recommendation follows an extensive evaluation of Pfizer’s global Animal Health plants following last year’s acquisition of Wyeth.
“We operate in a very challenging business environment and the restructuring of our Animal Health manufacturing network is critical to our efforts to remain competitive and customer-focused in the future,” said Pfizer Animal Health Manufacturing Vice President Carolyn Hawver. “At the same time, we need to ensure that our colleagues at the Weesp site receive our support so that they can transition smoothly into the next phase of their careers.”
The site employs approximately 110 colleagues and is co-located on a site operated by Abbott Healthcare Products, b.v. in Weesp. Pfizer proposes to exit the facility over the next 18 months to two years and to transfer production of its poultry vaccines to Charles City, Iowa, and Campinas, Brazil; and its non-poultry vaccines to Olot, Spain and other network sites.
In an effort to preserve jobs and minimize the impact on the local community, Pfizer will aggressively explore opportunities to sell the plant as a going concern. Success will depend upon a number of market factors, including the present demand for animal health manufacturing facilities.
Pfizer’s reconfigured Animal Health Network will consist of plants in the following locations: Charles City, Iowa; Lincoln, Nebraska; Laurinburg, North Carolina, White Hall, Illinois; Campinas, Brazil; Suzhou, China; Hsinchu, Taiwan; Melbourne, Australia; Wellington, New Zealand; Louvain-la-Neuve, Belgium; Olot, Spain; and Haridwar, India. Pfizer also plans to invest up to $20 million (U.S.) to build a new Veterinary Medicine Research and Development pilot plant in Louvain-la-Neuve over the next two to three years.
Four other Pfizer plants in the study will continue to manufacture products for the Animal Health business: Kalamazoo, Michigan; Guarulhos, Brazil; Catania, Italy; and Nagoya, Japan.
The Animal Health network recommendations make up the second phase of Pfizer’s Plant Network Strategy. In May, Pfizer announced the restructuring of its Solid Dose, Aseptic, Biotechnology, and Consumer Healthcare plant networks, which included the proposed exit or reduction in size of 14 plants globally by the end of 2015 and an overall decrease in employment of approximately 6,000 jobs.
# # # #
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States